CSIMarket
 
Pfizer Inc  (NYSE: PFE)
Other Ticker:  
 
 
Price: $24.4700 $-0.11 -0.448%
Day's High: $24.78 Week Perf: -3.47 %
Day's Low: $ 24.69 30 Day Perf: 1.96 %
Volume (M): 2,465 52 Wk High: $ 31.54
Volume (M$): $ 61,040 52 Wk Avg: $26.28
Open: $24.49 52 Wk Low: $20.92



 Market Capitalization (Millions $) 139,724
 Shares Outstanding (Millions) 5,710
 Employees 88,000
 Revenues (TTM) (Millions $) 62,463
 Net Income (TTM) (Millions $) 7,912
 Cash Flow (TTM) (Millions $) 702
 Capital Exp. (TTM) (Millions $) 2,769

Pfizer Inc
Company Profile: Pfizer Inc.

Overview:
Pfizer Inc. is a leading research-based global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative prescription medicines for both humans and animals. Additionally, Pfizer is well-known for its extensive portfolio of consumer healthcare products, which are trusted by millions around the world.

Incorporation:
Pfizer was incorporated under the laws of the State of Delaware on June 2, 1942. Since its inception, the company has grown to become one of the largest and most influential pharmaceutical companies in the world.

Mission and Vision:
Pfizers mission is to apply science and global resources to bring therapies to people that extend and significantly improve their lives. The company is committed to ensuring access to its innovative medicines and vaccines, fostering health equity and patient empowerment.

Key Areas of Focus:
Pfizer operates in various therapeutic areas, including but not limited to:

- Oncology: Developing treatments for various types of cancer.
- Vaccines: Notably recognized for its COVID-19 vaccine, as well as vaccines for other infectious diseases such as pneumococcal disease and meningitis.
- Cardiovascular Disease: Providing solutions for heart disease, hypertension, and related conditions.
- Immunology: Offering therapies for autoimmune diseases.
- Rare Diseases: Innovating treatments for conditions that affect a small population of patients.

Global Presence:
Pfizer operates in numerous countries worldwide, employing a diverse workforce committed to advancing healthcare. The company collaborates with healthcare professionals, governments, and academic institutions to address global health challenges.

Recent Achievements:
Pfizer has achieved significant milestones in recent years, particularly with the rapid development of its mRNA COVID-19 vaccine. This innovative approach not only contributed to the global pandemic response but also demonstrated the potential of new vaccine technologies.

Commitment to Sustainability:
Pfizer is committed to sustainability and has implemented numerous initiatives to reduce its environmental impact. The company engages in responsible sourcing, minimizing waste, and improving energy efficiency throughout its operations.

Conclusion:
Pfizer Inc. stands at the forefront of the pharmaceutical industry, driven by a vision to improve healthcare outcomes and enhance the quality of life for people around the globe. With a focus on innovation, collaboration, and sustainability, Pfizer continues to make significant contributions to the health and well-being of communities worldwide.


   Company Address: 66 Hudson Boulevard East New York 10001 NY
   Company Phone Number: 733-2323   Stock Exchange / Ticker: NYSE PFE


Customers Net Income grew by PFE's Customers Net Profit Margin grew to


2.66 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.18%    
ABT   -6.33%    
BMY        0.04% 
JNJ        4.39% 
LLY   -3.46%    
MRK   -4.43%    
• View Complete Report
   



Partnership

Vepdegestrants Promise Redefining Advanced Breast Cancer Treatment Through Improved Progression-Free Survival,

Published Sat, May 31 2025 1:06 PM UTC

Innovative Treatment Advantage: Vepdegestrant s Role in Redefining Progression-Free Survival in ESR1-Mutant Advanced Breast Cancer The pursuit of improving therapeutic outcomes for advanced breast cancer has reached a significant milestone with the results from the Phase 3 VERITAC2 clinical trial, heralding a promising new era in oncology. Arvinas, Inc. (Nasdaq: ARVN) and P...

Business Update

Pfizers Sasanlimab Combination Therapy Shows Promising Results in Bladder Cancer amidst Development Setbacks,

Published Sun, Apr 27 2025 9:46 AM UTC

Pfizer s Sasanlimab Combination Significantly Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer Pfizer Inc. (NYSE: PFE), a leading global biopharmaceutical company headquartered in New York, has announced promising results from a pivotal Phase 3 CREST trial involving their investigational anti-PD1 monoclonal antibody (mAb), sasanlimab. This trial t...

Business Update

Pfizers Forward Momentum in Cancer Care Amid Setbacks in Other Drug Developments

Published Thu, Apr 24 2025 7:28 AM UTC

In an exciting and promising announcement, Pfizer Inc. (NYSE: PFE) has spotlighted its latest advancements in oncology at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Scheduled from May 30 to June 3 in Chicago, Pfizer will present data from more than 60 research abstracts, including 9 oral and 6 rapid oral presentations that delve into their...

Business Update

ACIP Expands Pfizers ABRYSVO Vaccine Recommendation to Include At-Risk Adults Aged 50-59,

Published Thu, Apr 17 2025 7:26 AM UTC

Pfizer s ABRYSVO RSV Vaccine Receives Expansive ACIP Recommendation for Adults 50-59 In a significant move towards strengthening respiratory healthcare, Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention?s (CDC) Advisory Committee on Immunization Practices (ACIP) has extended its recommendation for Pfizer s respiratory syncytial virus...

Business Update

Pfizer to Showcase Strategic Vision at J.P. Morgan Healthcare Conference,

Published Mon, Jan 6 2025 3:47 PM UTC

Pfizer s Upcoming Presentation at J.P. Morgan Healthcare Conference Highlights Engagement with Investors Pfizer Inc. (NYSE: PFE), one of the world s premier biopharmaceutical companies, has announced an opportunity for investors and the general public to view and listen to a webcast featuring a discussion with Albert Bourla, Pfizer s Chairman and Chief Executive Officer. Thi...







Pfizer Inc's Segments
Other Business Activities    1.99 % of total Revenue
Biopharma    98 % of total Revenue
U S    61.06 % of total Revenue
International Developed Markets    23.17 % of total Revenue
International Emerging Markets    15.77 % of total Revenue
Biopharma U S Commercial Division    60.41 % of total Revenue
Biopharma International Commercial Division    37.59 % of total Revenue
Pfizer CentreOne    1.87 % of total Revenue
Pfizer Ignite    0.12 % of total Revenue
Total Alliance revenues    15.41 % of total Revenue
Royalty    2.25 % of total Revenue
Primary Care Biopharma    41.53 % of total Revenue
Primary Care Eliquis Biopharma    14.02 % of total Revenue
Primary Care Prevnar Family Biopharma    12.1 % of total Revenue
Primary Care Comirnaty Biopharma    4.12 % of total Revenue
Primary Care Paxlovid Biopharma    3.58 % of total Revenue
Primary Care Nurtec ODT Vydura Biopharma    1.81 % of total Revenue
Primary Care Abrysvo Biopharma    0.96 % of total Revenue
Primary Care All other Primary Care Biopharma    4.94 % of total Revenue
Specialty Care Biopharma    29.07 % of total Revenue
Specialty Care Vyndaqel family Biopharma    10.83 % of total Revenue
Specialty Care Sulperazon Biopharma    1.2 % of total Revenue
Specialty Care Zithromax Biopharma    1.15 % of total Revenue
Specialty Care Inflectra Biopharma    1.12 % of total Revenue
Specialty Care Enbrel Outside the U S and Canada Biopharma    1.02 % of total Revenue
Specialty Care Zavicefta Biopharma    0.98 % of total Revenue
Specialty Care Xeljanz Biopharma    0.93 % of total Revenue
Specialty Care Cibinqo Biopharma    0.42 % of total Revenue
Specialty Care All other Hospital Biopharma    8.42 % of total Revenue
Specialty Care All other Specialty Care Biopharma    2.98 % of total Revenue
Oncology Biopharma    27.4 % of total Revenue
Oncology Ibrance Biopharma    7.12 % of total Revenue
Oncology Xtandi Biopharma    3.34 % of total Revenue
Oncology Padcev Biopharma    3.11 % of total Revenue
Oncology Oncology Biosimilars Biopharma    1.92 % of total Revenue
Oncology Lorbrena Biopharma    1.62 % of total Revenue
Oncology Inlyta Biopharma    1.6 % of total Revenue
Oncology Adcetris Biopharma    1.59 % of total Revenue
Oncology Bosulif Biopharma    1.1 % of total Revenue
Oncology Braftovi Mektovi Biopharma    0.99 % of total Revenue
Oncology Aromasin Biopharma    0.79 % of total Revenue
Oncology Tukysa Biopharma    0.74 % of total Revenue
Oncology Elrexfio Biopharma    0.44 % of total Revenue
Oncology Talzenna Biopharma    0.29 % of total Revenue
Oncology Tivdak Biopharma    0.24 % of total Revenue
Oncology All other Oncology Biopharma    2.52 % of total Revenue

  Pfizer Inc Outlook

On January 30 2024 the Pfizer Inc provided following guidance

Pfizer Inc. (NYSE: PFE) released its financial re...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com